Live feed15:05:00·1mPRReleasevia QuantisnowLilly's Jaypirca (pirtobrutinib), the first-and-only approved non-covalent BTK inhibitor, receives expanded indication from U.S. FDA for certain patients with previously untreated CLL/SLLByQuantisnow·Wall Street's wire, on your screen.LLY· Eli Lilly and CompanyHealth Care
